Page 1626 - Williams Hematology ( PDFDrive )

1600 Part XI: Malignant Lymphoid Diseases Chapter 96: Pathology of Lymphomas 1601

21. Hajdu SI, Melamed MR: Limitations of aspiration cytology in the diagnosis of primary
neoplasms. Acta Cytol 28:337, 1984.
22. Klein U, Tu Y, Stolovitzky GA, et al: Gene expression profiling of B cell chronic lympho-
cytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med
194:1625, 2001.
23. Rosenwald A, Alizadeh AA, Widhopf G, et al: Relation of gene expression phenotype
to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp
Med 194:1639, 2001.
24. Wiestner A, Rosenwald A, Barry TS, et al: ZAP-70 expression identifies a chronic lym-
phocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical
outcome, and distinct gene expression profile. Blood 101:4944, 2003.
25. Dohner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic
lymphocytic leukemia. N Engl J Med 343:1910, 2000.
26. Treon SP, Lian X, Yang G, et al: MYD88 L265P somatic mutation in Waldenström’s
macroglobulinemia. N Engl J Med 367:826, 2012.
27. Weisenburger DD, Armitage JO: Mantle cell lymphoma: An entity comes of age. Blood
87:4483, 1996.
28. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic
study of 80 cases. Blood 89:2067, 1997.
29. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature
Figure 96–41. Nodular lymphocyte predominance Hodgkin lym- is a quantitative integrator of oncogenic events that predicts survival in mantle cell lym-
phoma stained with antibody CD20. Note the positive staining of the phoma. Cancer Cell 3:185, 2003.
lymphocyte predominant (LP) cells (popcorn cells). 30. Gesk S, Klapper W, Martin-Subero JI, et al: A chromosomal translocation in cyclin
D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the
IGK locus. Blood 108:1109, 2006.
31. Mozos A, Royo C, Hartmann E, et al: SOX11 expression is highly specific for mantle cell
nodular architectural pattern with a background consisting primarily lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94:1555, 2009.
of lymphocytes. Histiocytes are also a common feature, but neutrophils 32. Carvajal-Cuenca A, Sua LF, Silva NM, et al: In situ mantle cell lymphoma: clinical
and eosinophils are absent or rare. implications of an incidental finding with indolent clinical behavior. Haematologica
97:270, 2012.
33. Jaffe ES, Shevach EM, Frank MM, et al: Nodular lymphoma: Evidence for origin from
REFERENCES follicular B lymphocytes. N Engl J Med 290:813, 1974.
34. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al: Follicular lymphoma grade 3B
1. Magrath IT: Historical perspective: The evolution of modern concepts of biology and includes 3 cytogenetically defined subgroups with primary t(14;18) 3q27, or other
management, in The Non-Hodgkin’s Lymphomas, 2nd ed, edited by Magrath IT, p 47. translocations: t(14;18) and 3q27 are mutually exclusive. Blood 101:1149, 2003.
Arnold, London, 1997. 35. Ott G, Katzenberger T, Lohr A, et al: Cytomorphologic, immunohistochemical, and
2. Hodgkin T: On some morbid appearances of the absorbent glands and spleen. Trans cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3.
Med Soc Lond 17:68, 1832. Blood 99:3806, 2002.
3. Rappaport H, Winter W, Hicks E: Follicular lymphoma: A re-evaluation of its position 36. Jegalian AG, Eberle FC, Pack SD, et al: Follicular lymphoma in situ: Clinical implica-
in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 9:792, tions and comparisons with partial involvement by follicular lymphoma. Blood 118;
1956. 2976, 2011.
4. Rappaport H: Tumors of the Hematopoietic System, Fasc 8. Armed Forces Institute of 37. Thieblemont C, Felman P, Callet-Bauchu E, et al: Splenic marginal zone lymphoma: A
Pathology, Washington, 1966. distinct clinical and pathological entity. Lancet Oncol 4:95, 2003.
5. Arnold A, Cossman J, Bakhshi A, et al: Immunoglobulin-gene rearrangements as 38. Nathwani BN, Drachenberg MR, Hernandez AM, et al: Nodal monocytoid B-cell lym-
unique clonal markers in human lymphoid neoplasms. N Engl J Med 309:1593, 1983. phoma (nodal marginal-zone B-cell lymphoma). Semin Hematol 36:128, 1999.
6. Aisenberg AC, Krontiris TG, Mak TW, Wilkes BM: Rearrangement of the gene for the 39. Zucca E, Bertoni F, Roggero E, Cavalli F: The gastric marginal zone B cell lymphoma of
beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related MALT type. Blood 96:410, 2000.
disorders. N Engl J Med 313:529, 1985. 40. Bertoni F, Cotter FE, Zucca E: Molecular genetics of extranodal marginal zone (MALT-
7. Gerard-Marchant R, Hamlin I, Lennert K, et al: Classification of non-Hodgkin’s lym- type) B-cell lymphoma. Leuk Lymphoma 35:57, 1999.
phoma. Lancet ii:406, 1974. 41. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict
8. Lukes RJ, Collins RD: Immunologic characterization of human malignant lymphomas. survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937,
Cancer 34(Suppl 4):1488, 1974. 2002.
9. Schein PS, Chabner BA, Canellos GP, et al: Potential for prolonged disease-free sur- 42. Lenz G, Wright G, Dave SS, et al: Stromal gene signatures in large-B-cell lymphomas.
vival following combination chemotherapy of non-Hodgkin’s lymphoma. Blood 43:181, N Engl J Med 359:2313, 2008.
1974. 43. Barton S, Hawkes EA, Wotherspoon A, Cunningham D: Are we ready to stratify treat-
10. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lympho- ment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist 17:1562,
mas: Summary and description of a working formulation for clinical usage. The Non- 2012.
Hodgkin’s Lymphoma Pathologic Classification Project. Cancer 49:2112, 1982. 44. Choi WWL, Weisenburger DD, Greiner TC, et al: A new immunostain algorithm clas-
11. Stansfeld AG, Diebold J, Noel H, et al: Updated Kiel classification for lymphomas. sifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin
Lancet 1:292, 1988. Cancer Res 15:5494, 2009.
12. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lym- 45. De Jong D, Rosenwald A, Chhanabhai M, et al: Immunohistochemical prognostic
phoid neoplasms: A proposal from the International Lymphoma Study Group. Blood markers in diffuse large B-cell lymphoma: Validation of tissue microarray as a pre-
84:1361, 1994. requisite for broad clinical applications—A study from the Lunenburg Lymphoma
13. A clinical evaluation of the International Lymphoma Study Group classification of non- Biomarker Consortium. J Clin Oncol 25:805, 2007.
Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Classification Project. Blood 46. Scott DW, Wright GW, Williams PM, et al: Determining cell-of-origin subtypes of dif-
89:3909, 1997. fuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded
14. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of Haemato- tissue. Blood 123:1214, 2014.
poietic and Lymphoid Tissues, 4th ed. IARC Press, Lyon, 2008. 47. Savage KJ, Johnson NA, Ben-Neriah S, et al: MYC gene rearrangements are associated
15. Liang P, Pardee AB: Analyzing differential gene expression in cancer. Nat Rev Cancer with a poor prognosis in diffuse large B cell lymphoma patients treated with R-CHOP
3:869, 2003. chemotherapy. Blood 114:3533, 2009.
16. MacLennan IC: Germinal centers. Annu Rev Immunol 12:117, 1994. 48. Aukema SM, Siebert R, Schuuring E, et al: Double-hit B-cell lymphomas. Blood
17. Jennings CD, Foon KA: Recent advances in flow cytometry: Application to the diagno- 117:2319, 2011.
sis of hematologic malignancy. Blood 90:2863, 1997. 49. Johnson NA, Slack GW, Savage KS, et al: Concurrent expression of MYC and BCL2 in
18. Mauvieux L, Macintyre EA: Practical role of molecular diagnostics in non-Hodgkin’s diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxoru-
lymphomas. Baillieres Clin Haematol 9:653, 1996. bicin, vincristine, and prednisone. J Clin Oncol 30: 3452, 2012.
19. Collins RD: Is clonality equivalent to malignancy: Specifically, is immunoglobulin gene 50. van Besien K, Kelta M, Bahaguna P: Primary mediastinal B-cell lymphoma: A review of
rearrangement diagnostic of malignant lymphoma? Hum Pathol 28:757, 1997. pathology and management. J Clin Oncol 19:1855, 2001.
20. Lester JF, Dojcinov SD, Attanoos RL, et al: The clinical impact of expert pathologi- 51. Rosenwald A, Wright G, Leroy K, et al: Molecular diagnosis of primary mediastinal
cal review on lymphoma management: A regional experience. Br J Haematol 123:463, B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lym-
2003. phoma related to Hodgkin lymphoma. J Exp Med 198:851, 2003.

Kaushansky_chapter 96_p1587-1602.indd 1601 9/18/15 6:08 PM